Cisplatin, a platinum-based chemotherapy agent that is used to treat testicular cancer, non-small cell lung cancer, bladder cancer, cervical cancer, ovarian cancer and head and neck cancer, has been found to cause a significant amount of hearing loss in patients, according to a recent article published in Nature Communications.
Based on results from the phase III OlympiAD trial, the FDA approved olaparib (Lynparza), a PARP inhibitor, for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy. HR-positive patients must also have had prior endocrine therapy.
Blueberries are known as a "superfood" because of the rich essential vitamins and minerals they provide. Research now shows they may also help to treat cancer.
Only a quarter of patients who have brain cancer enroll in hospice care with enough time to benefit from the comfort, symptom management and emotional support it can provide, a new study shows.
Patients diagnosed with thyroid cancer before the age of 40 appear to be at the highest risk for age-related diseases, including heart disease and diabetes, compared with their age-matched counterparts.
Though women presenting with breast pain are often sent by their clinicians for different types of breast cancer testing — typically undergoing mammography, an ultrasound, and a physical exam — a new study reveals that breast pain is not necessarily an indicator of cancer.
The FDA has granted a breakthrough therapy designation to the combination of pembrolizumab (Keytruda), a PD-1 inhibitor, and lenvatinib (Lenvima), a VEGF/FGF inhibitor, for the treatment of patients with advanced and/or metastatic renal cell carcinoma (RCC).
NextSource Pharma has raised the price of oral chemotherapy agent lomustine (Gleostine) by 1400% since acquiring the drug, which is used to treat Hodgkin lymphoma and glioblastoma, from Bristol-Myers Squibb in 2013.
Carfilzomib, commonly used to treat patients with multiple myeloma, may lead to an increased risk of cardiovascular events.
Denosumab (Xgeva), a RANK ligand inhibitor, has been approved by the FDA for the prevention of skeletal-related events (SREs) in patients with multiple myeloma.
The duo of lenalidomide (Revlimid) and rituximab (Rituxan) is a combination that is feasible, safe and active as initial and maintenance therapy for use in patients with mantle cell lymphoma, according to a new study.
Some younger women with breast cancer may soon have a new first-line treatment option. Ribociclib (Kisqali), has been granted a breakthrough therapy designation by the FDA for use in combination with tamoxifen or an aromatase inhibitor (AI) as frontline treatment for pre- or perimenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Seattle Genetics announced that a supplemental biologics license application for brentuximab vedotin (Adcetris) used in combination with Adriamycin, vinblastine, and dacarbazine as a frontline treatment for advanced classical Hodgkin lymphoma has been granted a priority review by the FDA.
Progenics Pharmaceuticals announced that the FDA has granted a priority review designation to a novel version of the radiopharmaceutical iobenguane I-131 (Azedra), for patients with malignant or recurrent pheochromocytoma or paraganglioma.
A new study shows that using the targeted agents lapatinib (Tykerb) and trastuzumab (Herceptin) together, combined with an aromatase inhibitor (AI), significantly reduced the risk of death or progression in women with HER2-positive/HR-positive metastatic breast cancer compared with each single targeted agent in combination with an AI.
Researchers investigate the cellular biology of aging and the effects of cancer treatment associated with accelerated aging.
The combination of olaparib (Lynparza) and durvalumab (Imfinzi) for pretreated patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer shows great promise for future treatment.
The FDA has granted priority review to a supplemental new drug application (sNDA) for use of dabrafenib (Tafinlar) and trametinib (Mekinist) in combination as an adjuvant treatment for patients with BRAFV600E– or V600K–positive stage III melanoma following complete resection.
Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cancer, according to a recent report about a 7.5-year Korean study.
The FDA has approved a novel breast-specific stereotactic body radiotherapy (SBRT) device known as GammaPod as a treatment for patients with early breast cancer, based on findings from a 17-patient study.
The FDA has granted a priority review to a new drug application (NDA) for apalutamide (ARN-509) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Apalutamide is an oral androgen receptor inhibitor.
Mothaffar Fahed Rimawi, MD, explains the importance of targeting treatments for patients with low levels of HER2 protein based on their genetic mutations, and the possible use of immunotherapy for these patients.
The FDA has approved the combination of pertuzumab (Perjeta), trastuzumab (Herceptin) and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence.
Nivolumab (Opdivo) is now approved by the Food and Drug Administration (FDA) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.
Based on findings from the phase III BFORE trial, the FDA has approved Bosutinib as a first-line treatment for a chronic myeloid leukemia subtype.
The FDA approved abozantinib (Cabometyx) for use in previously untreated patients who have advanced renal cell carcinoma (RCC).
Using oral rivaroxaban (Xarelto) to treat patients with cancer reduced venous thromboembolism (VTE) recurrence in a select-d trial.
The FDA has granted a priority review to a supplemental new drug application (sNDA) for the use of osimertinib as a first-line treatment for patients with non-small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations.
Patients with cancer who suffer severe distress are more likely to miss appointments during the course of their radiation therapy and be admitted to the hospital.
New trial results represent the first successful effort in more than 30 years to imrove outcomes of first-line treatment in patients with advanced Hodgkin lymphoma (HL).
